Section of Urologic Oncology, Rutgers Cancer Institute of New Jersey and Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ.
Division of Biometrics, Rutgers Cancer Institute of New Jersey and Rutgers School of Public Health, New Brunswick, NJ.
Clin Genitourin Cancer. 2022 Jun;20(3):296-296.e9. doi: 10.1016/j.clgc.2022.01.001. Epub 2022 Jan 7.
Several guidelines have adopted early integration of palliative intervention (PI) into oncologic care to improve quality of life among patients with advanced malignancies. However, PI utilization patterns and factors associated with its use in metastatic renal cell carcinoma are poorly understood.
Using the National Cancer Database (NCDB), we abstracted patients diagnosed with Stage IV RCC from 2004 to 2014 and evaluated the utilization of PI within this cohort. Socioeconomic and clinical factors were compared for patients receiving and not receiving PI for metastatic RCC. Multivariable logistic regression (MLR) models identified factors that were associated with receipt of PI within overall cohort and treatment-based cohorts.
We identified 42,014 patients with Stage IV RCC, of which 7,912 patients received PI. From 2004 to 2014, the use of PI minimally increased from 17% to 20% for Stage IV RCC. MLR analysis demonstrated that increased comorbidities, insurance status, higher education status, facility location, care at a comprehensive cancer program or integrated network, sarcomatoid histology, and treatment type significantly increased the likelihood of PI use. Various socioeconomic, clinical, and geographical factors that are associated with use of PI-based on the treatment received for Stage IV RCC.
While PI utilization has minimally increased for Stage IV RCC, there are several geographic, socioeconomic, and clinical factors that predict its use among patients with Stage IV RCC in a treatment-specific manner. Taken together, this suggests the need for earlier initiation of PI in a more equitable and systematic fashion among patients with metastatic RCC.
有几个指南采用了姑息治疗(PI)的早期综合介入,以提高晚期恶性肿瘤患者的生活质量。然而,转移性肾细胞癌(RCC)中 PI 的利用模式和相关因素尚不清楚。
使用国家癌症数据库(NCDB),我们从 2004 年到 2014 年提取了诊断为 IV 期 RCC 的患者,并评估了该队列中 PI 的利用情况。对接受和未接受转移性 RCC PI 的患者进行了社会经济和临床因素的比较。多变量逻辑回归(MLR)模型确定了总体队列和治疗队列中与接受 PI 相关的因素。
我们确定了 42014 例 IV 期 RCC 患者,其中 7912 例接受了 PI。从 2004 年到 2014 年,IV 期 RCC 的 PI 使用量从 17%微增至 20%。MLR 分析表明,合并症增多、保险状况、较高的教育程度、医疗机构位置、在综合性癌症计划或综合网络中接受治疗、肉瘤样组织学和治疗类型显著增加了 PI 使用的可能性。各种社会经济、临床和地理因素与基于 IV 期 RCC 治疗的 PI 使用相关。
尽管 IV 期 RCC 的 PI 使用率略有增加,但仍有几个地理、社会经济和临床因素以特定于治疗的方式预测 IV 期 RCC 患者的 PI 使用。总之,这表明需要在转移性 RCC 患者中以更公平和系统的方式更早地开始 PI。